Related Experiment Video
Updated: Nov 5, 2025
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
[Cerebral Amyloid Angiopathy-Related Inflammation/Vasculitis]
1Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences.
Insights
Cerebral amyloid angiopathy-related inflammation/vasculitis (CAA-ri/vasculitis) is a treatable condition. Early immunosuppressant therapy, often with corticosteroids, significantly improves patient outcomes and prevents irreversible brain damage.
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Cerebral amyloid angiopathy (CAA) involves amyloid deposition in brain blood vessels, commonly as amyloid β (Aβ).
- CAA-related inflammation/vasculitis (CAA-ri/vasculitis) is an emerging, treatable complication of Aβ deposition.
- Prevalence in Japan is estimated at 0.13 per 100,000 population.
Purpose of the Study:
- To describe the clinical presentation, diagnosis, and treatment of CAA-ri/vasculitis.
- To highlight the importance of early intervention for improved patient prognosis.
- To review current diagnostic standards and therapeutic approaches.
Main Methods:
- Review of clinical cases and diagnostic findings for CAA-ri/vasculitis.
- Analysis of neuroimaging (MRI) and cerebrospinal fluid (CSF) biomarkers.
- Evaluation of treatment outcomes, particularly response to immunosuppressive therapy.
Main Results:
- CAA-ri/vasculitis presents with cognitive impairment, behavioral changes, and headache.
- MRI shows white matter abnormalities and meningeal enhancement; CSF may show elevated anti-Aβ antibodies and inflammatory markers.
- Neuropathology confirms Aβ deposition, vasculitis, and inflammation; brain biopsy is the gold standard.
Conclusions:
- CAA-ri/vasculitis is a distinct, treatable entity associated with Aβ deposition.
- Prompt diagnosis and immunosuppressant therapy, especially corticosteroids, lead to significant improvement in nearly 80% of patients.
- Early treatment is critical to prevent long-term neurological sequelae.
Abstract:
Cerebral amyloid angiopathy (CAA) is a disorder characterized by the deposition of amyloid in the leptomeningeal and cortical blood vessels. Sporadic amyloid β (Aβ)-type CAA is the most common form of CAA. Although CAA is a well-known cause for recurrent cerebral lobar hemorrhage, inflammation, and vasculitis, CAA-related inflammation/vasculitis (CAA-ri/vasculitis) induced by Aβ deposition on vessel walls is emerging as a treatable condition. The estimated total number of cases of and prevalence of CAA-ri/vasculitis in Japan were 170 and 0.13 per 100 000 population, respectively. Patients with CAA-ri/vasculitis show acute or subacute-onset of cognitive impairment, behavioral changes, and headache. Brain magnetic resonance imaging, showing asymmetrical white matter abnormalities and occasional meningeal enhancement, is a useful tool for the diagnosis of CAA-ri/vasculitis. Moreover, elevation of anti-Aβ antibodies and inflammatory markers in the cerebrospinal fluid can help in clinical diagnosis. Although several clinical diagnostic criteria have been proposed, neuropathological examination of a brain biopsy remains the gold standard for detecting severe Aβ deposition and vasculopathic changes with lymphocytic infiltrations and/or granulomatous vasculitis. No validated treatment regimen has been established to date. Nearly 80% patients with CAA-ri/vasculitis improved after immunosuppressant therapy with corticosteroid and/or cyclophosphamide. Early treatment is essential to prevent irreversible sequelae in the brain.
